The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
about
Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1SLC transporters as therapeutic targets: emerging opportunitiesAdvances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications18F-Labeled Peptides: The Future Is BrightThe IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligandsGPCRdb: the G protein-coupled receptor database - an introductionG Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic TargetsInternational Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptorsA drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand target space in ChEMBLUsing the fragment molecular orbital method to investigate agonist-orexin-2 receptor interactionsCOMSAT: Residue contact prediction of transmembrane proteins based on support vector machines and mixed integer linear programming.Harnessing public domain data to discover and validate therapeutic targets.Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov.Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition dataHarnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.Molecular assembly of rhodopsin with G protein-coupled receptor kinases.Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.Nanobodies to Study G Protein-Coupled Receptor Structure and Function.Allosteric sodium in class A GPCR signalingThe Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled ReceptorSystematic functional profiling of transcription factor networks in Cryptococcus neoformans.A two-step strategy to enhance activity of low potency peptides.Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.Drug affinity responsive target stability (DARTS) for small-molecule target identification.PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome.Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.Drug Normalization for Cancer Therapeutic and Druggable Genome Target Discovery.Topology based identification and comprehensive classification of four-transmembrane helix containing proteins (4TMs) in the human genomeSystems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Ligand Similarity Complements Sequence, Physical Interaction, and Co-Expression for Gene Function Prediction.Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1.Recent Advances in Effect-directed Enzyme Assays based on Thin-layer Chromatography.Data on overlapping brain disorders and emerging drug targets in human Dopamine Receptors Interaction NetworkDGIdb 2.0: mining clinically relevant drug-gene interactions.In vitro expression and analysis of the 826 human G protein-coupled receptors.Drugging Membrane Protein Interactions.Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell linesSystematic functional analysis of kinases in the fungal pathogen Cryptococcus neoformans.Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.Kinase inhibitors as potential agents in the treatment of multiple myeloma.
P2860
Q26774799-29B4484E-D8AD-4427-8738-3D1325C4827BQ27014726-623546A9-83D1-4D0D-89C5-F994F4463352Q27021848-A4C7BF6F-7A64-4800-99B4-FDB833921E22Q27023393-EDC5FA49-95A0-4A83-830F-94D7E5D5957EQ27136827-E099A4A0-44FB-44B4-A81F-D5B3DDD4DCD1Q28077608-F02A8B1D-52A1-4BA3-B5CB-4FD963F9825FQ28081099-C3CF5EC4-25F0-49EF-AF08-10B3833AB251Q28257710-92A6B7A1-9C50-401D-AB32-5EBE511D8295Q28598307-89E9D9EE-724D-4752-A960-038ECCD56E3CQ28818280-3D987B7C-00C9-4E27-AB92-85ECED2E17E8Q30383444-479024B3-61D3-4966-9F95-F182271E14F5Q30491667-8847E7C0-CF4E-425D-A759-83C9381313AFQ30884583-20028F96-F719-4962-826A-916E512B73CFQ30982375-B114E114-03B0-4990-B843-16EEEEAA59C8Q31053398-6160E345-2B04-4DCB-BDAF-A497B2390954Q33365434-17DAFAFB-2BAF-417B-9DDE-FF22F1584FE1Q33632351-74A90F36-2091-4DA0-9B5B-1C1AFCA8AB81Q33880125-694EDA4E-7526-4595-90BB-A9B68040D476Q33931569-119FC553-F24C-4C8A-9860-B1DCD2A542F7Q34500216-DB84C446-5088-4C32-A31B-2BDCF5F4DFFBQ35338420-7D637C83-93AA-4BD4-BE3E-A705187E37D0Q35414793-B21B3789-5572-4BB0-841F-220CF7013E85Q35493874-B2A58DA6-64D6-4BF1-AA34-01CEB718C92BQ35548750-BC7F5A5C-BC1B-42D3-A3C1-5903BC4D6AF8Q35582384-D45DA8D3-C57C-4A1C-B4DF-04D06C2E714DQ35802177-25E82E11-0027-4089-A6BD-DB36CE2BE6D1Q35917239-1C60ECF5-436C-4716-B7F2-190B791DBC9EQ35974649-39FBE7C2-2651-4355-A2C9-5E84B43EE03FQ36087088-60890FC5-B885-4339-87C8-38CDC9E52496Q36088820-56594FE0-E0F3-4E11-AE4E-6E8B16FC3D8FQ36217628-5CE79B29-189C-4443-B943-360E873ECAEAQ36266184-0BF3385A-A3B7-4C02-98A0-AD83A1693F9AQ36365376-698F7594-846A-4928-96E2-74F338D1D7C3Q36434749-53E1BA90-37CF-473E-8610-72285C4EEB4AQ36858819-F688D862-6151-4428-8113-6F128D220C7EQ37143137-F3C254F0-F926-4F9E-9B65-E96ADF3F13A0Q37165815-E157B593-4AC6-42C7-9EAE-20F93A7C603CQ37315258-909E66B7-F654-4133-8AD1-82EDB3487F1DQ37565204-2A8C3029-F3E8-4F7E-A8FE-09B34F141083Q37697253-324483D6-23E1-414E-B3EC-B2239E969D4F
P2860
The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The druggable genome: Evaluati ...... olecular class and indication.
@en
type
label
The druggable genome: Evaluati ...... olecular class and indication.
@en
prefLabel
The druggable genome: Evaluati ...... olecular class and indication.
@en
P1476
The druggable genome: Evaluati ...... olecular class and indication.
@en
P2093
Mathias Rask-Andersen
Surendar Masuram
P356
10.1146/ANNUREV-PHARMTOX-011613-135943
P577
2013-08-30T00:00:00Z